BODE³ Programme, Department of Public Health, University of Otago Wellington, Wellington, New Zealand.
Centre for Public Health Research, Massey University, Wellington, New Zealand.
Popul Health Metr. 2019 Aug 5;17(1):10. doi: 10.1186/s12963-019-0192-x.
Doubts exist around the value of compiling league tables for cost-effectiveness results for health interventions, primarily due to methods differences. We aimed to determine if a reasonably coherent league table could be compiled using published studies for one high-income country: New Zealand (NZ).
Literature searches were conducted to identify NZ-relevant studies published in the peer-reviewed journal literature between 1 January 2010 and 8 October 2017. Only studies with the following metrics were included: cost per quality-adjusted life-year or disability-adjusted life-year or life-year (QALY/DALY/LY). Key study features were abstracted and a summary league table produced which classified the studies in terms of cost-effectiveness.
A total of 21 cost-effectiveness studies which met the inclusion criteria were identified. There were some large methodological differences between the studies, particularly in the time horizon (1 year to lifetime) but also discount rates (range 0 to 10%). Nevertheless, we were able to group the incremental cost-effectiveness ratios (ICERs) into general categories of being reported as cost-saving (19%), cost-effective (71%), and not cost-effective (10%). The median ICER (adjusted to 2017 NZ$) was ~ $5000 per QALY/DALY/LY (~US$3500). However, for some interventions, there is high uncertainty around the intervention effectiveness and declining adherence over time.
It seemed possible to produce a reasonably coherent league table for the ICER values from different studies (within broad groupings) in this high-income country. Most interventions were cost-effective and a fifth were cost-saving. Nevertheless, study methodologies did vary widely and researchers need to pay more attention to using standardised methods that allow their results to be included in future league tables.
由于方法上的差异,对于编制卫生干预措施成本效益结果的排名表的价值存在疑问。我们旨在确定是否可以使用已发表的研究为一个高收入国家(新西兰)编制一个合理一致的排名表。
进行文献检索,以确定 2010 年 1 月 1 日至 2017 年 10 月 8 日期间在同行评议期刊文献中发表的与新西兰相关的研究。仅包括具有以下指标的研究:每质量调整生命年、残疾调整生命年或生命年的成本(QALY/DALY/LY)。提取关键研究特征,并制作一个总结排名表,根据成本效益对研究进行分类。
确定了 21 项符合纳入标准的成本效益研究。这些研究之间存在一些较大的方法差异,特别是在时间范围(1 年至终生)和贴现率(范围 0 至 10%)方面。尽管如此,我们仍然能够将增量成本效益比(ICER)分为报告为成本节约(19%)、成本效益(71%)和无成本效益(10%)的一般类别。调整至 2017 年新西兰元的中位数 ICER 约为 5000 美元/QALY/DALY/LY(约 3500 美元)。然而,对于某些干预措施,干预效果和随时间推移的依从性下降存在高度不确定性。
似乎可以为这个高收入国家的不同研究(在广泛的分组内)的 ICER 值编制一个合理一致的排名表。大多数干预措施具有成本效益,其中五分之一是成本节约。尽管如此,研究方法确实存在很大差异,研究人员需要更加注意使用标准化方法,使他们的结果能够包含在未来的排名表中。